Currently, erdafitinib and pemigatinib are approved for use in the United States for metastatic urothelial carcinoma with FGFR2 or FGFR3 aberrations and for cholangiocarcinoma with an FGFR2 rearrangement, respectively [37, 38]. The gene discussed is FGFR3; the disease is cholangiocarcinoma.